Safety information

Balanced information belongs beside every treatment option.

This page establishes the disclosure standard. Final clinical content must match the exact formulation, route, and pharmacy selected for launch.

Compounded drugs

Compounded tirzepatide, NAD+, and sermorelin are not FDA approved. FDA does not verify compounded drugs for safety, effectiveness, or quality before marketing.

Compounded products can carry risks related to strength, contamination, sterility, storage, and administration. Your clinician should explain why a compounded option is being considered.

Weight care safety context

Common side effects of tirzepatide are nausea, diarrhea, constipation, vomiting, and stomach pain. Serious risks include pancreatitis, gallbladder problems, and dehydration.

Approved tirzepatide products carry a boxed warning for thyroid C-cell tumors, so it is not for anyone with a personal or family history of medullary thyroid cancer or MEN 2. It is not for use in pregnancy. Read more on the tirzepatide page.

Menopause care safety context

Estrogen medicines carry a boxed warning about endometrial cancer, heart disease, stroke, blood clots, breast cancer, and dementia. If you still have a uterus, estradiol is paired with progesterone to protect the uterine lining.

Hormone therapy is not for anyone with unexplained vaginal bleeding, a current estrogen-sensitive cancer, a recent blood clot, or uncontrolled high blood pressure. Read more on the menopause page.

NAD+ safety context

Compounded NAD+ is not FDA approved, and evidence for it as a treatment in healthy adults is limited. Injections can cause redness, soreness, flushing, nausea, cramping, or headache. The nasal spray can irritate the nose.

It is not for use in pregnancy or while breastfeeding. Read more on the NAD+ page.

Sermorelin safety context

Compounded sermorelin is not FDA approved. Common effects are redness or soreness where you inject, flushing, headache, and dizziness.

It is not for anyone with a history of cancer or a pituitary tumor, and not for use in pregnancy. Read more on the sermorelin page.

Before treatment

  • Tell the clinician about all medications and supplements.
  • Share allergies, reactions, conditions, and prior treatments.
  • Ask about evidence, uncertainty, risks, and alternatives.
  • Confirm the dispensing pharmacy and its contact information.
  • Understand storage, administration, and follow up instructions.

When to get help

Follow the final pharmacy and clinician instructions. Contact the care team promptly for concerning or unexpected symptoms.

Call 911 or go to the nearest emergency room for a medical emergency. This website does not provide emergency care.